Leaps by Bayer

Indapta Therapeutics is a privately held biotechnology company developing an NK (natural killer) cell therapy platform for the treatment of blood and solid tumor cancers.

Nuvig Therapeutics is advancing innovative and transformational therapies that are designed to induce natural mechanisms to restore immune homeostasis, rebalance immune function following inflammation, and improve the treatment options for patients. Nuvig is building a pipeline of novel immune therapeutics for chronic inflammatory and autoimmune diseases.

Egenesis Inc. is a biotechnology company focused on gene editing and genome engineering to create human transplantable organs, tissues, and cells. Established in 2015 and headquartered in Cambridge, Massachusetts, with an additional office in New York City, Egenesis aims to address the global organ shortage by developing solid organs and therapeutic cell transplantation solutions for various diseases. The company utilizes a gene editing platform that incorporates techniques such as single-cell cloning and somatic cell nuclear transfer, which are essential for creating human-compatible organ tissues and cells. Egenesis is particularly engaged in advancing programs related to kidney and islet cell transplantation, striving to provide alternative treatment options for patients with life-threatening conditions.

GRO Biosciences is focused on developing advanced protein therapeutics by utilizing innovative technologies in computational protein design and synthetic biology. The company has created several genomically recoded strains of bacteria that enable the incorporation of non-standard amino acids into proteins. This approach enhances the potency, stability, and targeted delivery of these therapeutics. GRO Biosciences aims to apply its technology to improve treatments for a range of conditions, including diabetes, growth disorders, and autoimmunity, thereby addressing significant unmet medical needs.

Huma is a global health technology company that offers a modular platform designed to support digital "hospitals at home" across various disease areas. The platform integrates predictive algorithms, digital biomarkers, and real-world data to enhance proactive and predictive healthcare. By connecting data from hospital databases, patient wearables, and mobile devices, Huma provides healthcare providers with real-time information to improve patient care. The company also collaborates with leading healthcare institutions to measure and improve health outcomes, ultimately aiming to enable healthcare professionals to deliver better health solutions for all.

Transcarent is a consumer-directed health and care platform designed for employees of self-insured employers and their families. The company utilizes a blend of software, technology, and data science to provide consumers with unbiased information and trusted guidance. By connecting users to a network of high-value healthcare providers and services, Transcarent aims to empower individuals to make informed choices and achieve better health outcomes while navigating the complexities of the healthcare system. This approach fosters transparency and cost-effective decision-making, addressing a wide range of healthcare challenges faced by consumers today.

Summer Health is a provider of pediatric telehealth services designed to simplify access to healthcare for families. The company enables timely communication with board-certified pediatricians through a text-based platform, allowing users to receive expert answers and reliable advice quickly. Summer Health's services include health tracking and personalized healthcare plans, ensuring that patients can obtain necessary care within minutes. By leveraging digital technology, Summer Health aims to enhance the healthcare experience for families navigating health concerns.

Capstan Therapeutics is a biotechnology company focused on enhancing the therapeutic potential of in vivo RNA-based therapies. It develops proprietary targeted delivery systems, including targeted lipid nanoparticles, to improve the efficacy and control of dosage in engineered cell therapies. This innovative platform aims to address a variety of diseases, particularly in the fields of oncology, fibrosis, and inflammation, where there are significant unmet clinical needs. By advancing precision in vivo cell engineering, Capstan Therapeutics seeks to create transformative therapeutics that can offer new solutions for patients facing these challenging conditions.

9amHealth is a healthcare service provider that aims to deliver comprehensive medical support for chronic conditions such as diabetes, hypertension, and hyperlipidemia. The company offers personalized care plans, prescription medication, at-home lab tests, and unlimited virtual visits, ensuring that patients have direct access to affordable and compassionate care. By redesigning all care elements into a single digital service, 9amHealth caters to the modern realities of patients' lives, making healthcare always available and convenient, even for those without insurance. Its focus on chronic conditions highlights its commitment to improving the health and well-being of customers in the United States.

NextPoint Therapeutics is a clinical-stage biotechnology company that develops therapeutics to treat cancer patients. The company offers immunotherapies for a validated checkpoint axis that is independent of PD-1/L1 and modulates both adaptive and innate immune systems to find and destroy cancer cells. It advances therapeutic approaches utilizing the unique upregulation of HHLA2 in cancer as an anchor for tumor-targeting therapeutic modalities.

Sudo Biosciences is a biopharmaceutical company focused on developing innovative medicines that target the tyrosine kinase 2 (TYK2) pseudokinase domain, an important component in cytokine signaling pathways associated with various immune-mediated inflammatory conditions. The company has a pipeline of next-generation TYK2 inhibitors, which includes a candidate designed to penetrate the brain for the treatment of multiple sclerosis and neurodegenerative diseases characterized by neuroinflammation, as well as a topical candidate aimed at addressing immune-mediated dermatologic diseases. Sudo Biosciences aims to provide effective and affordable treatment options for patients suffering from these conditions.

Jixing Pharmaceuticals is a global biotechnology company focused on developing and commercializing innovative therapeutics for cardiovascular and ophthalmic diseases. The company has a diverse pipeline that includes treatments for conditions such as hypertrophic cardiomyopathy, heart failure, presbyopia, hypertension, and dry eye disease. A key aspect of their development efforts includes a small molecule cardiac myosin inhibitor, in-licensed from Cytokinetics, specifically designed to treat hypertrophic cardiomyopathy. Jixing Pharmaceuticals aims to provide effective treatments for patients in China, addressing significant unmet medical needs in the realms of cardiovascular and ophthalmic health.

NewLeaf Symbiotics is an agriculture technology company based in Saint Louis, Missouri, that specializes in the research, development, and commercialization of beneficial symbiotic bacteria aimed at enhancing plant health and increasing crop yields. The company focuses on natural bacteria, particularly pink pigmented facultative methylotrophs, which are utilized in various agricultural products for row crops, vegetables, fruits, and flowers. Through laboratory, greenhouse, and field trials, NewLeaf Symbiotics aims to provide sustainable agricultural solutions that assist farmers in combating plant diseases and improving overall agricultural productivity. Founded in 2011 and originally known as TrophoMax, LLC, the company rebranded to its current name in 2012.

65LAB focuses on scientific advancement to create new therapeutic companies and lifesaving medicines.

Rantizo, Inc. is a company that specializes in the development and sale of agricultural drones and related equipment, including trailers, sprayers, spreaders, and battery chargers. Founded in 2018 and based in Iowa City, Iowa, Rantizo offers precision spraying services for crops using an innovative electrostatic spraying technique. This technology ensures even coverage of pesticides and chemicals, addressing common challenges faced by farmers in applying these substances. Additionally, Rantizo integrates software solutions with drone manufacturers and agronomy systems to enhance large-scale agricultural operations, facilitating efficient mapping, compliance, and coordination of spraying needs. Through its products and services, Rantizo aims to streamline agricultural practices and improve crop management for farmers.

DEKA Biosciences is an early-stage biotechnology company focused on developing next-generation cytokine therapeutics aimed at treating cancer and inflammatory diseases. The company is dedicated to creating life-changing medicines with disease-specific applications that enhance patient outcomes. By leveraging improved pharmacokinetics and pharmacodynamics, DEKA Biosciences aims to deliver dual and complementary cytokines directly to affected tissues or cells. This targeted approach seeks to provide patients with curative treatment options for a range of conditions, including cancer, autoimmune disorders, and infectious diseases.

ReCode Therapeutics is a biopharmaceutical company focused on developing precision medicines for pulmonary diseases, particularly targeting genetic conditions such as primary ciliary dyskinesia and cystic fibrosis. Founded in 2015 and based in Menlo Park, California, the company employs a unique non-viral lipid nanoparticle platform that facilitates the precise delivery of nucleic acid and protein payloads to specific organs and tissues, enhancing the effectiveness of genetic therapies. This selective organ targeting (SORT) technology allows for the administration of corrective or disease-modifying treatments beyond the liver, addressing the challenges faced by traditional gene therapy methods. By harnessing these innovative techniques, ReCode Therapeutics aims to provide new therapeutic options for patients suffering from rare and life-limiting respiratory diseases.

Guardian Agriculture specializes in developing autonomous electric vertical takeoff and landing (eVTOL) systems tailored for precision agriculture. Their innovative technology empowers farmers by providing automated aerial crop protection services, significantly enhancing operational efficiency while minimizing environmental impact. The eVTOL system utilizes lithium battery power to ensure safe and effective application over farm fields. Additionally, it captures valuable data to help farmers refine their chemical usage and improve crop sustainability. By integrating aerial utility services with precision agriculture, Guardian Agriculture aims to support growers in extending their operational reach and achieving more sustainable farming practices.

ChrysaLabs has developed a real-time, portable and accurate soil fertility assessment technology to enable growers and agronomists to better managed their fertilizers and increase their yield.

Andes develops an integrated microbial technology to help accelerate crop growth. Its technology is combined with artificial intelligence to develop its seeds while reducing input costs and environmental footprints and helps farmers to boost their agricultural output and income. Andes was founded in 2018 and is headquartered in Alameda, California.

Fork & Good is a Brooklyn-based food company founded in 2018 that focuses on developing a sustainable approach to food production. The company specializes in cultivated meat, which is made by growing real meat cells to create pure animal proteins and fats. These products are designed to be clean, traceable, and flavorful, providing consumers with affordable and healthy food options. Fork & Good aims to contribute to a more sustainable food system by offering alternatives that align with modern dietary preferences and environmental considerations.

Paratus Sciences is a biotechnology company focused on enhancing human health and health security through the study of bat biology. By exploring the unique aspects of the bat genome, the company aims to identify and develop therapeutics for a variety of diseases. Paratus Sciences seeks to unlock the secrets of bat biology to facilitate innovative treatments, ultimately helping patients combat the health challenges they encounter.

EarthOptics is a developer of a global soil cloud platform aimed at sustainable agricultural management. The company utilizes advanced sensors and machine learning techniques to create highly accurate soil maps based on minimal soil samples. Its technology provides insights into various soil attributes, including compaction, fertility, and carbon levels. This information enables farmers, ranchers, and land managers to make informed and sustainable soil management decisions, which can lead to improved profitability and environmental stewardship. Additionally, EarthOptics offers near-real-time actionable data that enhances soil health management and provides cost-effective verification for carbon credits.

NextPoint Therapeutics is a clinical-stage biotechnology company that develops therapeutics to treat cancer patients. The company offers immunotherapies for a validated checkpoint axis that is independent of PD-1/L1 and modulates both adaptive and innate immune systems to find and destroy cancer cells. It advances therapeutic approaches utilizing the unique upregulation of HHLA2 in cancer as an anchor for tumor-targeting therapeutic modalities.

Metagenomi, Inc. is a biotechnology company focused on developing gene editing systems aimed at treating genetic diseases. Founded in 2016 and based in Emeryville, California, Metagenomi utilizes metagenomics and machine learning to uncover novel genome editing technologies derived from previously uncharacterized organisms. The company's innovative discovery platform enables the creation of highly efficient and specific gene editing tools, including programmable nucleases, base editors, and advanced integration systems such as prime editing and CRISPR-associated transposases. By harnessing these naturally evolved systems, Metagenomi seeks to address a wide range of genetic mutations that traditional genome engineering approaches have struggled to target, with the ultimate goal of providing transformative therapies for patients globally.

Sound Agriculture uses molecular discovery to create climate-resilient crops, enhancing harvest yields for growers. They also use an innovative life science approach to sustainably increase farming productivity. The company was founded in 2013 and headquartered in Emeryville, California.

NuCicer is focused on transforming chickpeas from a niche ingredient into a staple superfood by developing new varieties with enhanced agronomic and quality traits. The company specializes in producing chickpeas that feature increased protein content, improved flavor, and tailored nutritional properties. Utilizing a diverse chickpea breeding library alongside a proprietary breeding innovation platform that integrates plant genetics and machine learning, NuCicer aims to address the growing demands for nutritious and sustainable food sources. Their efforts not only enhance the nutritional value of chickpeas but also aim to reduce the environmental impact of agriculture, supporting the needs of the alternative-meat sector and promoting a more sustainable food system.

Capstan Therapeutics is a biotechnology company focused on enhancing the therapeutic potential of in vivo RNA-based therapies. It develops proprietary targeted delivery systems, including targeted lipid nanoparticles, to improve the efficacy and control of dosage in engineered cell therapies. This innovative platform aims to address a variety of diseases, particularly in the fields of oncology, fibrosis, and inflammation, where there are significant unmet clinical needs. By advancing precision in vivo cell engineering, Capstan Therapeutics seeks to create transformative therapeutics that can offer new solutions for patients facing these challenging conditions.

ReCode Therapeutics is a biopharmaceutical company focused on developing precision medicines for pulmonary diseases, particularly targeting genetic conditions such as primary ciliary dyskinesia and cystic fibrosis. Founded in 2015 and based in Menlo Park, California, the company employs a unique non-viral lipid nanoparticle platform that facilitates the precise delivery of nucleic acid and protein payloads to specific organs and tissues, enhancing the effectiveness of genetic therapies. This selective organ targeting (SORT) technology allows for the administration of corrective or disease-modifying treatments beyond the liver, addressing the challenges faced by traditional gene therapy methods. By harnessing these innovative techniques, ReCode Therapeutics aims to provide new therapeutic options for patients suffering from rare and life-limiting respiratory diseases.

Senti Biosciences is a clinical-stage biotechnology company specializing in synthetic biology and gene circuit engineering for therapeutic purposes. The company employs its Gene Circuits platform to develop innovative therapies that enhance precision in targeting cancer cells while avoiding damage to healthy cells. Senti Bio's approach involves the use of allogeneic chimeric antigen receptor natural killer (CAR-NK) cells that incorporate its gene circuit technologies, aimed at addressing various oncology indications. Among its product candidates are SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to selectively eliminate cancer cells without harming healthy bone marrow, and SENTI-301A, which targets hepatocellular carcinoma. Senti Biosciences aims to provide effective treatment options for difficult-to-treat diseases through advanced cell and gene therapies.

9amHealth is a healthcare service provider that aims to deliver comprehensive medical support for chronic conditions such as diabetes, hypertension, and hyperlipidemia. The company offers personalized care plans, prescription medication, at-home lab tests, and unlimited virtual visits, ensuring that patients have direct access to affordable and compassionate care. By redesigning all care elements into a single digital service, 9amHealth caters to the modern realities of patients' lives, making healthcare always available and convenient, even for those without insurance. Its focus on chronic conditions highlights its commitment to improving the health and well-being of customers in the United States.

Affini-T Therapeutics is a biotechnology company developing T-cell therapies for patients suffering from cancer. Affini-T uses a validated platform to select high-affinity T cell receptors specific to oncogenic mutations to pioneer cutting-edge solid tumor therapies. Affini-T leverages gene editing and synthetic biology to engineer novel T-cell therapies designed to eradicate tumors.

Apollo Agriculture Ltd. is an agtech company based in Nairobi, Kenya, that supports smallholder farmers by providing financial and technical assistance. Founded in 2015, the company offers loans to help farmers acquire essential inputs such as fertilizer, seeds, and crop insurance, along with access to expert advice. By utilizing agronomic machine learning, remote sensing, and mobile technology, Apollo customizes financing packages based on individual farmer needs, assessing credit risk through satellite and soil data. This tailored approach aims to enhance farming practices and significantly increase crop yields, thereby maximizing profits for farmers in emerging markets.

Triumvira Immunologics is an immunotherapy company founded in 2015 and headquartered in Austin, Texas, with research facilities in Hamilton, Canada. The company focuses on developing innovative T cell therapies for cancer treatment, including chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies. Its lead product, CD19-TAC01, targets CD19 for the treatment of B cell malignancies. Triumvira's proprietary T cell Antigen Coupler (TAC) technology enhances the recruitment of the natural T cell receptor and operates independently of the major histocompatibility complex. This unique approach enables the creation of more effective therapies for a diverse range of patients suffering from both solid and liquid tumors, as well as other diseases.

Woebot Health is a digital mental healthcare provider that focuses on delivering personalized support through an innovative platform. This platform integrates advanced artificial intelligence and natural language processing with established therapeutic techniques to create engaging mental health tools. At the core of its offering is Woebot, a relational agent designed to provide continuous, empathic, and personalized care. By leveraging these technologies, Woebot Health enables individuals and businesses to access effective mental health support conveniently and seamlessly, fitting into everyday life and promoting overall well-being.

Founded in 2021, Cylinder delivers personalized, clinician-backed care to those suffering from digestive issues through its virtual health platform and has helped nearly 100K members to date. Cylinder's platform offers dynamically updated content and care plans designed to improve engagement and outcomes. Members enjoy access to a dedicated care team nationwide, including health coaches, registered dietitians, and GI doctors. Cylinder’s vision is to create a world where people receive convenient, personalized, and affordable access to the quality digestive health care they need to improve their overall health. Trusted by businesses including Texas A&M University, US Foods, and more, Cylinder showcases up to 5:1 ROI and an average of 13% employee engagement. Learn more at cylinderhealth.com.

Indapta Therapeutics is a privately held biotechnology company developing an NK (natural killer) cell therapy platform for the treatment of blood and solid tumor cancers.

Dewpoint Therapeutics is a Boston-based biotech company focused on the research and development of treatments targeting biomolecular condensates to address various diseases, including cancer, neurodegenerative disorders, and immunological conditions. Founded in 2018, the company employs an innovative drug platform that utilizes machine-learning-based image analysis for visualizing condensates. This technology supports an engine of engineered cell lines designed to track and mitigate harmful protein sequestration. By leveraging its proprietary platform, Dewpoint seeks to facilitate drug discovery across a wide range of medical indications and collaborates with leading academic and pharmaceutical partners to enhance the accessibility of new therapies for unmet healthcare needs.

Gandeeva Therapeutics is a precision biotechnology company focused on developing innovative therapeutics by leveraging cryogenic electron microscopy and machine learning to target key protein-protein interactions. The company's structure-guided drug discovery platform includes target prediction and validation, hit identification through virtual and fragment library screening, and lead optimization. Gandeeva has established a strong preclinical oncology pipeline aimed at addressing challenging cancers with unique protein interaction modulators, including interfacial glues and allosteric inhibitors. Headquartered in the Greater Vancouver area, Canada, Gandeeva is dedicated to enhancing the drug discovery process and reducing the risk of late-stage clinical failures.

Metagenomi, Inc. is a biotechnology company focused on developing gene editing systems aimed at treating genetic diseases. Founded in 2016 and based in Emeryville, California, Metagenomi utilizes metagenomics and machine learning to uncover novel genome editing technologies derived from previously uncharacterized organisms. The company's innovative discovery platform enables the creation of highly efficient and specific gene editing tools, including programmable nucleases, base editors, and advanced integration systems such as prime editing and CRISPR-associated transposases. By harnessing these naturally evolved systems, Metagenomi seeks to address a wide range of genetic mutations that traditional genome engineering approaches have struggled to target, with the ultimate goal of providing transformative therapies for patients globally.

Cellino is focused on creating an automated biomanufacturing system for personalized cell therapies, with the aim of making these treatments widely accessible. The company leverages an AI-guided laser editing platform that employs image-guided machine learning and robotics to generate autologous induced pluripotent stem cells (iPSCs) at scale. This innovative approach is designed to facilitate the development of potentially curative therapies for chronic degenerative diseases, such as vision loss and Parkinson's disease. By streamlining the process of cell therapy production, Cellino aims to enhance the availability of life-saving medicines for patients around the world.

Bloom Science, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing neuroprotective medicines that leverage the microbiome to address epilepsy and other neurological conditions. Established in 2017, the company employs its proprietary IrisRx™ discovery platform, which utilizes insights into the Gut-Brain Axis to create therapeutics targeting rare and complex neurological disorders. This innovative approach aims to translate the therapeutic benefits of the ketogenic diet into effective medications, enhancing safety and efficacy. Bloom Science is advancing a diverse pipeline of therapeutic candidates aimed at conditions such as Dravet syndrome, other rare epilepsies, Amyotrophic Lateral Sclerosis (ALS), and various neurodegenerative and cognitive disorders, with a commitment to providing improved treatment options for patients facing serious, life-altering illnesses.

GRO Biosciences is focused on developing advanced protein therapeutics by utilizing innovative technologies in computational protein design and synthetic biology. The company has created several genomically recoded strains of bacteria that enable the incorporation of non-standard amino acids into proteins. This approach enhances the potency, stability, and targeted delivery of these therapeutics. GRO Biosciences aims to apply its technology to improve treatments for a range of conditions, including diabetes, growth disorders, and autoimmunity, thereby addressing significant unmet medical needs.

DEKA Biosciences is an early-stage biotechnology company focused on developing next-generation cytokine therapeutics aimed at treating cancer and inflammatory diseases. The company is dedicated to creating life-changing medicines with disease-specific applications that enhance patient outcomes. By leveraging improved pharmacokinetics and pharmacodynamics, DEKA Biosciences aims to deliver dual and complementary cytokines directly to affected tissues or cells. This targeted approach seeks to provide patients with curative treatment options for a range of conditions, including cancer, autoimmune disorders, and infectious diseases.

Mozart Therapeutics is a biotechnology startup dedicated to developing disease-modifying therapies for autoimmune and inflammatory diseases. The company focuses on a novel regulatory CD8 T cell network to create innovative CD8 Treg modulators aimed at treating a range of autoimmune conditions. By targeting a specific subset of T-lymphocytes, Mozart aims to restore long-term immune balance and prevent the progression of damage caused by autoreactive immune responses. Its pipeline includes first-in-class CD8 Treg modulators designed to delay the onset of autoimmune diseases and improve patient outcomes through advanced treatment options.

Clarify Medical is innovating a well-established treatment, UVB therapy, to become easier, more convenient, more empowering, and more connected for psoriasis, eczema and vitiligo patients. The company also focused on developing innovative technology, products, and services that improve care for people with chronic skin conditions. Clarify Medical indicated for the localized phototherapeutic treatment of dermatologic conditions such as psoriasis, vitiligo, atopic dermatitis (eczema), seborrheic dermatitis, and leukoderma on all skin types (I-VI). It is the first and only connected phototherapy system that uses an app on the patient’s own smartphone (iOS or Android) to manage the dose, frequency, and duration of UVB light therapy, helping to ensure that patients receive the proper doses recommended by the American Academy of Dermatology and Vitiligo Working Group. The treatment regimen is prescribed by the patient’s physician but monitored and controlled by the Clarify System, enabling patients to administer treatment with clinical precision in the convenience of their homes. The connected system monitors dosing, adherence, compliance, patient progress, and satisfaction.

EarthOptics is a developer of a global soil cloud platform aimed at sustainable agricultural management. The company utilizes advanced sensors and machine learning techniques to create highly accurate soil maps based on minimal soil samples. Its technology provides insights into various soil attributes, including compaction, fertility, and carbon levels. This information enables farmers, ranchers, and land managers to make informed and sustainable soil management decisions, which can lead to improved profitability and environmental stewardship. Additionally, EarthOptics offers near-real-time actionable data that enhances soil health management and provides cost-effective verification for carbon credits.

Sound Agriculture uses molecular discovery to create climate-resilient crops, enhancing harvest yields for growers. They also use an innovative life science approach to sustainably increase farming productivity. The company was founded in 2013 and headquartered in Emeryville, California.

Andes develops an integrated microbial technology to help accelerate crop growth. Its technology is combined with artificial intelligence to develop its seeds while reducing input costs and environmental footprints and helps farmers to boost their agricultural output and income. Andes was founded in 2018 and is headquartered in Alameda, California.

Woebot Health is a digital mental healthcare provider that focuses on delivering personalized support through an innovative platform. This platform integrates advanced artificial intelligence and natural language processing with established therapeutic techniques to create engaging mental health tools. At the core of its offering is Woebot, a relational agent designed to provide continuous, empathic, and personalized care. By leveraging these technologies, Woebot Health enables individuals and businesses to access effective mental health support conveniently and seamlessly, fitting into everyday life and promoting overall well-being.

Transcarent is a consumer-directed health and care platform designed for employees of self-insured employers and their families. The company utilizes a blend of software, technology, and data science to provide consumers with unbiased information and trusted guidance. By connecting users to a network of high-value healthcare providers and services, Transcarent aims to empower individuals to make informed choices and achieve better health outcomes while navigating the complexities of the healthcare system. This approach fosters transparency and cost-effective decision-making, addressing a wide range of healthcare challenges faced by consumers today.

Kojin Therapeutics, founded by Stuart Schreiber, Benjamin Cravatt, Stephanie Dougan, and Vasanthi Viswanathan, focuses on advancing a drug discovery platform that links complex cell states to established biochemical processes, specifically ferroptosis, which involves iron-dependent cell death. This innovative approach enables the development of targeted therapies for a wide range of challenging diseases that are often difficult to treat. The company's biology platform aims to identify disease-specific targets, ensuring that patients receive effective treatments tailored to their specific conditions. Kojin Therapeutics is supported by a diverse group of investors, including Polaris Partners, Newpath Partners, and AbbVie, among others.

Ada Health is a global health company based in Berlin, Germany, founded in 2011 by a team of doctors, scientists, and industry experts. The company has developed a virtual health companion platform that empowers users to actively manage their health and assists medical professionals in delivering effective care. Ada's platform utilizes personalized health inquiries to assess symptoms and offers features such as online video consultations, disease monitoring, and prevention strategies. The company collaborates with leading health systems and global non-profit organizations to enhance healthcare delivery and improve health outcomes for individuals.

Huma is a global health technology company that offers a modular platform designed to support digital "hospitals at home" across various disease areas. The platform integrates predictive algorithms, digital biomarkers, and real-world data to enhance proactive and predictive healthcare. By connecting data from hospital databases, patient wearables, and mobile devices, Huma provides healthcare providers with real-time information to improve patient care. The company also collaborates with leading healthcare institutions to measure and improve health outcomes, ultimately aiming to enable healthcare professionals to deliver better health solutions for all.

Edifice Health is a spin-out company from a 10-year research study on immune profiling from Stanford University, the Stanford 1,000 Immunomes Project. The technology is the first biomarker composite scoring system to measure immune health and the Inflammatory Age® of an individual which predicts the onset of multiple chronic diseases and provides comprehensive health insights designed to help people change the course of their aging process.

Guardian Agriculture specializes in developing autonomous electric vertical takeoff and landing (eVTOL) systems tailored for precision agriculture. Their innovative technology empowers farmers by providing automated aerial crop protection services, significantly enhancing operational efficiency while minimizing environmental impact. The eVTOL system utilizes lithium battery power to ensure safe and effective application over farm fields. Additionally, it captures valuable data to help farmers refine their chemical usage and improve crop sustainability. By integrating aerial utility services with precision agriculture, Guardian Agriculture aims to support growers in extending their operational reach and achieving more sustainable farming practices.

Pyxis Oncology is a developer of antibody therapeutics intended to promote the body's immune response to cancer. The company has engaged in deep analyses of tumor antigen-specific tumor-infiltrating lymphocytes (TILs) within hot tumors and of tumor cell signaling pathways within cold tumors, providing laboratories with development of novel antibody-based immunotherapies. It was founded in 2019 and is based in Boston, Massachusetts.

CoverCress Inc. is a biotechnology company based in St. Louis, Missouri, focused on developing and commercializing field pennycress as an oilseed crop. Founded in 2013, the company aims to produce oil for industrial and renewable fuels, as well as meal for nutritious livestock feed. CoverCress specializes in crop breeding services that enhance soil cover during corn harvest and soybean planting, allowing farmers to maximize yields through sustainable agricultural practices. The company is dedicated to utilizing low-input methods to create a feedstock for low carbon intensity biofuels, contributing to more efficient and environmentally friendly agricultural solutions.

Century Therapeutics is a biotechnology company focused on developing advanced cell therapies using induced pluripotent stem cells (iPSCs) to treat various cancers, including hematologic and solid tumors. Founded in 2018 and based in Philadelphia, Pennsylvania, the company utilizes a unique allogeneic iPSC-derived cell therapy platform that integrates gene editing, protein engineering, and robust manufacturing capabilities. This innovative approach allows for the generation of modified immune effector cells, such as natural killer (NK) and T cells, designed to meet significant unmet medical needs. By employing techniques like CRISPR-mediated gene editing and proprietary chimeric antigen receptors, Century Therapeutics aims to enhance cell product performance and minimize rejection by the host immune system, thereby improving the efficacy of cancer treatments.

Egenesis Inc. is a biotechnology company focused on gene editing and genome engineering to create human transplantable organs, tissues, and cells. Established in 2015 and headquartered in Cambridge, Massachusetts, with an additional office in New York City, Egenesis aims to address the global organ shortage by developing solid organs and therapeutic cell transplantation solutions for various diseases. The company utilizes a gene editing platform that incorporates techniques such as single-cell cloning and somatic cell nuclear transfer, which are essential for creating human-compatible organ tissues and cells. Egenesis is particularly engaged in advancing programs related to kidney and islet cell transplantation, striving to provide alternative treatment options for patients with life-threatening conditions.

Amfora, Inc. is a biotechnology company based in San Francisco, California, established in 2016. The company focuses on developing nutritional forage crops through innovative biotechnological processes, particularly gene editing. Its mission is to address the increasing global demand for high-protein foods by enhancing the nutritional density of crops such as soybeans, wheat, and rice. By improving the protein content of these food and feed crops, Amfora aims to contribute to a more sustainable food system, reducing both costs and the environmental impact associated with food production.

Pairwise Plants is an agricultural gene editing company based in San Diego, California, focused on enhancing crops such as corn, soybeans, wheat, cotton, and canola. Founded in 2017 by a team of experts in food technology and genetics, Pairwise aims to improve the quality and nutritional value of fruits and vegetables, including leafy greens, berries, and stone fruits. The company collaborates with food and agriculture organizations to provide innovative solutions for both row and specialty crops. Pairwise holds licenses for advanced gene editing technologies from prestigious institutions, enabling the development of new crop varieties. With a commitment to building a healthier world through better food, Pairwise anticipates launching its first products in the coming years.

Ukko is a biotechnology company focused on enhancing the lives of individuals with food allergies and gluten-related disorders. Utilizing a sophisticated computational engineering platform, Ukko redesigns food allergens into therapeutics that are safe and effective. The company is developing a detailed, clinically validated map of the molecular structures associated with food allergies, which provides insights into the biological mechanisms of human-food interactions. By leveraging this information, Ukko creates modified proteins that do not provoke an immune response, offering a novel approach to treating protein-based allergies. Through the integration of artificial intelligence, immunology, computational biology, and protein engineering, Ukko aims to produce safe protein alternatives that physicians can confidently prescribe to patients.

Rantizo, Inc. is a company that specializes in the development and sale of agricultural drones and related equipment, including trailers, sprayers, spreaders, and battery chargers. Founded in 2018 and based in Iowa City, Iowa, Rantizo offers precision spraying services for crops using an innovative electrostatic spraying technique. This technology ensures even coverage of pesticides and chemicals, addressing common challenges faced by farmers in applying these substances. Additionally, Rantizo integrates software solutions with drone manufacturers and agronomy systems to enhance large-scale agricultural operations, facilitating efficient mapping, compliance, and coordination of spraying needs. Through its products and services, Rantizo aims to streamline agricultural practices and improve crop management for farmers.

Metagenomi, Inc. is a biotechnology company focused on developing gene editing systems aimed at treating genetic diseases. Founded in 2016 and based in Emeryville, California, Metagenomi utilizes metagenomics and machine learning to uncover novel genome editing technologies derived from previously uncharacterized organisms. The company's innovative discovery platform enables the creation of highly efficient and specific gene editing tools, including programmable nucleases, base editors, and advanced integration systems such as prime editing and CRISPR-associated transposases. By harnessing these naturally evolved systems, Metagenomi seeks to address a wide range of genetic mutations that traditional genome engineering approaches have struggled to target, with the ultimate goal of providing transformative therapies for patients globally.

Azitra is a clinical-stage medical dermatology company that leverages extensive scientific knowledge about the skin microbiome to discover and develop novel products for the treatment of adverse skin conditions and diseases.The Company’s technology platform, developed in collaboration with scientists at Yale University and the Jackson Laboratory, is based on a proprietary strain of the natural commensal bacteria Staphylococcus epidermidis.

Dewpoint Therapeutics is a Boston-based biotech company focused on the research and development of treatments targeting biomolecular condensates to address various diseases, including cancer, neurodegenerative disorders, and immunological conditions. Founded in 2018, the company employs an innovative drug platform that utilizes machine-learning-based image analysis for visualizing condensates. This technology supports an engine of engineered cell lines designed to track and mitigate harmful protein sequestration. By leveraging its proprietary platform, Dewpoint seeks to facilitate drug discovery across a wide range of medical indications and collaborates with leading academic and pharmaceutical partners to enhance the accessibility of new therapies for unmet healthcare needs.

Recursion Pharmaceuticals is a clinical-stage biotechnology company based in Salt Lake City, Utah, focused on transforming drug discovery through the integration of technology, particularly artificial intelligence, automation, and bioinformatics. Founded in 2013, the company utilizes a sophisticated drug discovery platform that includes various software solutions and robotic automation to enhance chemical compound selection, streamline experimental workflows, and evaluate drug efficacy. Key components of this platform involve tools for designing chemical compounds, planning complex experiments, and analyzing data to understand drug interactions and biological responses. By creating one of the largest proprietary biological and chemical datasets, Recursion aims to uncover new biological insights and expedite the development of innovative treatments, ultimately improving patient outcomes.

Triumvira Immunologics is an immunotherapy company founded in 2015 and headquartered in Austin, Texas, with research facilities in Hamilton, Canada. The company focuses on developing innovative T cell therapies for cancer treatment, including chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies. Its lead product, CD19-TAC01, targets CD19 for the treatment of B cell malignancies. Triumvira's proprietary T cell Antigen Coupler (TAC) technology enhances the recruitment of the natural T cell receptor and operates independently of the major histocompatibility complex. This unique approach enables the creation of more effective therapies for a diverse range of patients suffering from both solid and liquid tumors, as well as other diseases.

Unfold focuses on innovating vegetable varieties that deliver optimized quality and sensory experience in the vertical farming industry. They combine leading seed genetics with the agronomic expertise to dramatically advance productivity, flavor, and other consumer preferences. It was founded in 2020 and is headquartered in Sacramento, California.

Vesigen Therapeutics is a biotechnology company focused on developing innovative therapeutic products that address the challenges of targeted intracellular drug delivery. The company's proprietary technology, known as ARMMs (ARRDC1 Mediated Microvesicles), facilitates the direct delivery of various payloads, including RNAs, proteins, and gene-editing complexes, into the cytoplasm of target cells. This capability allows for an expanded range of druggable targets and supports the development of new therapies aimed at meeting currently unmet medical needs. By enhancing the delivery mechanisms for next-generation therapeutics, Vesigen Therapeutics aims to contribute significantly to advancements in the field of medicine.

Apollo Agriculture Ltd. is an agtech company based in Nairobi, Kenya, that supports smallholder farmers by providing financial and technical assistance. Founded in 2015, the company offers loans to help farmers acquire essential inputs such as fertilizer, seeds, and crop insurance, along with access to expert advice. By utilizing agronomic machine learning, remote sensing, and mobile technology, Apollo customizes financing packages based on individual farmer needs, assessing credit risk through satellite and soil data. This tailored approach aims to enhance farming practices and significantly increase crop yields, thereby maximizing profits for farmers in emerging markets.

CoverCress Inc. is a biotechnology company based in St. Louis, Missouri, focused on developing and commercializing field pennycress as an oilseed crop. Founded in 2013, the company aims to produce oil for industrial and renewable fuels, as well as meal for nutritious livestock feed. CoverCress specializes in crop breeding services that enhance soil cover during corn harvest and soybean planting, allowing farmers to maximize yields through sustainable agricultural practices. The company is dedicated to utilizing low-input methods to create a feedstock for low carbon intensity biofuels, contributing to more efficient and environmentally friendly agricultural solutions.

Oerth Bio is a developer of targeted protein degraders for agricultural applications. The company leverages Arvinas' novel PROTAC protein degrader technology to develop new human therapeutics for patients with cardiovascular, oncological, and gynecological diseases.

NewLeaf Symbiotics is an agriculture technology company based in Saint Louis, Missouri, that specializes in the research, development, and commercialization of beneficial symbiotic bacteria aimed at enhancing plant health and increasing crop yields. The company focuses on natural bacteria, particularly pink pigmented facultative methylotrophs, which are utilized in various agricultural products for row crops, vegetables, fruits, and flowers. Through laboratory, greenhouse, and field trials, NewLeaf Symbiotics aims to provide sustainable agricultural solutions that assist farmers in combating plant diseases and improving overall agricultural productivity. Founded in 2011 and originally known as TrophoMax, LLC, the company rebranded to its current name in 2012.

Immunitas is unlocking human immunology using novel single cell analyses to develop targeted therapeutics for patients with challenging, complex cancers. Translating findings from laboratory research to meaningful clinical advances in humans is a longstanding challenge in the oncology field. Immunitas was founded to directly address this problem and unlock a variety of novel drug targets based on discovery rooted in human biology. They are pursuing this goal with a team of pioneers in these areas across their scientific founders, management, and investors. At Immunitas, they employ a single cell sequencing platform to dissect the biology of immune cells in human tumors. Their focus on human samples allows us to start with and stay closer to the most relevant and translatable biology for patients and accelerates the pace of their research. They are identifying novel, exciting oncology targets and, importantly, developing key biomarkers to guide the selection of patients who may benefit from their new drugs. They are leveraging expertise in antibody discovery and engineering to create powerful therapies that modulate these targets, and are currently advancing a number of programs toward early human studies.

Egenesis Inc. is a biotechnology company focused on gene editing and genome engineering to create human transplantable organs, tissues, and cells. Established in 2015 and headquartered in Cambridge, Massachusetts, with an additional office in New York City, Egenesis aims to address the global organ shortage by developing solid organs and therapeutic cell transplantation solutions for various diseases. The company utilizes a gene editing platform that incorporates techniques such as single-cell cloning and somatic cell nuclear transfer, which are essential for creating human-compatible organ tissues and cells. Egenesis is particularly engaged in advancing programs related to kidney and islet cell transplantation, striving to provide alternative treatment options for patients with life-threatening conditions.

Huma is a global health technology company that offers a modular platform designed to support digital "hospitals at home" across various disease areas. The platform integrates predictive algorithms, digital biomarkers, and real-world data to enhance proactive and predictive healthcare. By connecting data from hospital databases, patient wearables, and mobile devices, Huma provides healthcare providers with real-time information to improve patient care. The company also collaborates with leading healthcare institutions to measure and improve health outcomes, ultimately aiming to enable healthcare professionals to deliver better health solutions for all.

BlueRock Therapeutics is a biotech company that plans to develop induced pluripotent stem cell (iPSC) therapies to cure a range of diseases using an industry-leading platform. One of the initial programs is to regenerate heart muscle in patients who have had a heart attack (myocard infarction, MI) or are suffering from chronic heart failure, leading causes of morbidity and mortality worldwid.

Pyxis Oncology is a developer of antibody therapeutics intended to promote the body's immune response to cancer. The company has engaged in deep analyses of tumor antigen-specific tumor-infiltrating lymphocytes (TILs) within hot tumors and of tumor cell signaling pathways within cold tumors, providing laboratories with development of novel antibody-based immunotherapies. It was founded in 2019 and is based in Boston, Massachusetts.

AgBiome, LLC is a biotechnology company based in Durham, North Carolina, that focuses on developing biological products to address significant challenges in agriculture, particularly soil-borne diseases affecting greenhouse and major row crops. Utilizing advanced genomics and screening technologies, AgBiome identifies plant-associated microbes that can enhance plant health, improve pest resistance, and increase crop yields. The company operates a state-of-the-art laboratory and greenhouse facility and collaborates with prominent agricultural firms to expedite its research and product development. AgBiome's offerings include fungicides that protect crops from various diseases and a platform for capturing and screening diverse microbes for agricultural applications. Established in 2012, AgBiome aims to provide sustainable solutions that support global food production and address critical agricultural issues such as insect and nematode control.

Resson Aerospace is a bioinformatics and data analytics company, delivering customized agriculture solutions for large corporate clients. Utilizing recent advances in large-scale cloud-based data processing, swarm robotics, and advanced data analytics, its proprietary Resson Agricultural Management and Analytics System gives the agricultural operator analytical insight and dynamic control over the farm area. Resson Aerospace’s Resson Agricultural Management and Analytics System, data-driven agriculture solution, analyzes crop metrics to assess crop status and health, providing operators with the information required to optimize agricultural operations, improve efficiency, boost yields, and maximize profitability. It is headquartered in Fredericton, N.B.

Pairwise Plants is an agricultural gene editing company based in San Diego, California, focused on enhancing crops such as corn, soybeans, wheat, cotton, and canola. Founded in 2017 by a team of experts in food technology and genetics, Pairwise aims to improve the quality and nutritional value of fruits and vegetables, including leafy greens, berries, and stone fruits. The company collaborates with food and agriculture organizations to provide innovative solutions for both row and specialty crops. Pairwise holds licenses for advanced gene editing technologies from prestigious institutions, enabling the development of new crop varieties. With a commitment to building a healthier world through better food, Pairwise anticipates launching its first products in the coming years.

Joyn Bio is a joint venture founded by Bayer and Ginkgo Bioworks developing probiotics for plants to provide growers with next generation solutions to their biggest challenges. Joyn Bio’s first area of focus will be on engineering microbes that provide cereal crops with their nitrogen needs to reduce agriculture’s reliance on nitrogen fertilizer and its environmental impact. Joyn Bio brings together microbiologists, synthetic biologists, plant scientists, and ecologists at its headquarters in Boston, Massachusetts and its plant research facility in West Sacramento, California.

NewLeaf Symbiotics is an agriculture technology company based in Saint Louis, Missouri, that specializes in the research, development, and commercialization of beneficial symbiotic bacteria aimed at enhancing plant health and increasing crop yields. The company focuses on natural bacteria, particularly pink pigmented facultative methylotrophs, which are utilized in various agricultural products for row crops, vegetables, fruits, and flowers. Through laboratory, greenhouse, and field trials, NewLeaf Symbiotics aims to provide sustainable agricultural solutions that assist farmers in combating plant diseases and improving overall agricultural productivity. Founded in 2011 and originally known as TrophoMax, LLC, the company rebranded to its current name in 2012.

Built by farmers for farmers, FarmLead is reinventing how grain is marketed and sold through the world’s fastest growing grain marketplace. Available online and as a mobile app, FarmLead also provides farmers access to exclusive market research, grain testing, price visibility and reduced brokerage fees and risks. The FarmLead Marketplace facilitates greater equality, efficiency and transparency for the grain industry. Farmers find more verified buyers and identify the best possible deal, while grain buyers easily access and identify the grain for sale in their desired location.

BlueRock Therapeutics is a biotech company that plans to develop induced pluripotent stem cell (iPSC) therapies to cure a range of diseases using an industry-leading platform. One of the initial programs is to regenerate heart muscle in patients who have had a heart attack (myocard infarction, MI) or are suffering from chronic heart failure, leading causes of morbidity and mortality worldwid.

Resson Aerospace is a bioinformatics and data analytics company, delivering customized agriculture solutions for large corporate clients. Utilizing recent advances in large-scale cloud-based data processing, swarm robotics, and advanced data analytics, its proprietary Resson Agricultural Management and Analytics System gives the agricultural operator analytical insight and dynamic control over the farm area. Resson Aerospace’s Resson Agricultural Management and Analytics System, data-driven agriculture solution, analyzes crop metrics to assess crop status and health, providing operators with the information required to optimize agricultural operations, improve efficiency, boost yields, and maximize profitability. It is headquartered in Fredericton, N.B.

Plant Response is focused on advancing agricultural ecosystems through innovative biological solutions. The company develops technologies aimed at reducing stress in plants and promoting growth globally. Their product offerings include plant healthcare solutions derived from natural compounds, which enhance plant immunity and tolerance to various stresses. Additionally, these technologies improve nutrient utilization, supporting agricultural professionals in their efforts to protect plant health and optimize growth. Plant Response's initiatives are rooted in research and aim to address the challenges faced in modern agriculture.

AgBiome, LLC is a biotechnology company based in Durham, North Carolina, that focuses on developing biological products to address significant challenges in agriculture, particularly soil-borne diseases affecting greenhouse and major row crops. Utilizing advanced genomics and screening technologies, AgBiome identifies plant-associated microbes that can enhance plant health, improve pest resistance, and increase crop yields. The company operates a state-of-the-art laboratory and greenhouse facility and collaborates with prominent agricultural firms to expedite its research and product development. AgBiome's offerings include fungicides that protect crops from various diseases and a platform for capturing and screening diverse microbes for agricultural applications. Established in 2012, AgBiome aims to provide sustainable solutions that support global food production and address critical agricultural issues such as insect and nematode control.